Variable agreement among experts regarding Mycobacterium avium complex lung disease

Data regarding many clinical aspects of pulmonary Mycobacterium avium complex (pMAC) are lacking. Guidelines rely substantially upon expert opinion, integrated through face‐to‐face meetings, variably weighting individual opinions. We surveyed North American non‐tuberculous mycobacteria experts regarding clinical aspects of pMAC using Delphi methods. Nineteen of 26 invited experts (73%) responded, with extensive variability. Convergence could not be reached for most questions. Respondents described extensive uncertainty around specific issues. Findings underscore urgent need for more research.

[1]  Robert Horsburgh,et al.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.

[2]  M. Beach,et al.  Direct healthcare costs of selected diseases primarily or partially transmitted by water , 2012, Epidemiology and Infection.

[3]  D. Hunter,et al.  Qualitative Research: Consensus methods for medical and health services research , 1995 .

[4]  S. Holland,et al.  Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. , 2012, American journal of respiratory and critical care medicine.

[5]  P. Steer,et al.  Recent advances in obstetrics. , 1996 .

[6]  K. Winthrop,et al.  Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. , 2010, American journal of respiratory and critical care medicine.

[7]  T. Marras,et al.  Isolation prevalence of pulmonary nontuberculous mycobacteria in Ontario in 2007. , 2011, Canadian respiratory journal.

[8]  Mary Ann Blosky,et al.  Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. , 2010, American journal of respiratory and critical care medicine.

[9]  T. Marras,et al.  Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997–2003 , 2007, Thorax.

[10]  T. Marras,et al.  Pulmonary Nontuberculous Mycobacterial Disease, Ontario, Canada, 1998–2010 , 2013, Emerging infectious diseases.

[11]  T. Marras,et al.  The cost of medical management of pulmonary nontuberculous mycobacterial disease in Ontario, Canada , 2010, European Respiratory Journal.

[12]  S. Field,et al.  Mycobacterium avium complex pulmonary disease in patients without HIV infection. , 2004, Chest.

[13]  S. Holland,et al.  Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. , 2009, Respiratory medicine.

[14]  P. Kao,et al.  Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. , 1999, Chest.

[15]  T. Marras,et al.  Aging, COPD, and other risk factors do not explain the increased prevalence of pulmonary Mycobacterium avium complex in Ontario. , 2012, Chest.

[16]  N. Ampel.  Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases , 2007 .

[17]  D. Wenger.  Limitations of Evidence-based Medicine: The Role of Experience and Expert Opinion , 2012, Journal of pediatric orthopedics.